Cambridge, UK, 5th December 2019: Mogrify Ltd (Mogrify), a UK company aiming to transform the development of cell therapies, received MSD’s Innovation Award at the 15th Annual Scrip Awards, and the Lifetime Achievement Award was presented to Dr. Jane Osbourn, OBE, Chair at Mogrify. The Innovation Award recognizes the significant potential the Company’s direct cellular conversion technology has to disrupt the future development of new medicines. Dr.
News
Arecor announces positive headline results for the first Phase I clinical trial of AT247, a novel ultra rapid acting formulation of insulin
Favourable pharmacokinetic/pharmacodynamic profile compared to current best in class insulin treatment
Cambridge, UK, and Stockholm, Sweden, 03 December 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it has entered into a partnership with The Human Protein Atlas (HPA). HPA has selected Horizon’s CRISPR-edited knockout cell models to further expand the knowledge available in its Cell Atlas program, to advance our understanding of the genetic drivers of disease.
Cambridge, UK, 03 December 2019: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells. The agreement is to generate and optimise antibodies for novel immuno-oncology targets, including access to IONTAS’ proprietary Mammalian Display technology to select antibodies with optimal biophysical properties.
Cambridge and London, UK, 03 December 2019: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical research charity, today announced an extension of their neuroscience-focused ion channel drug discovery collaboration, following the success of the initial twelve-month agreement.
Cambridge, UK: Global courier for cell and gene therapy, Biocair, will exhibit at Cell Therapy Manufacturing and Gene Therapy Congress between 3-6 December 2019. Taking place in Amsterdam, Cell Therapy Manufacturing and Gene Therapy Congress brings together key players from the industry to discuss the critical issues facing the development, scale-up and manufacture of cell-based and gene therapies.
NEW STATE-OF-THE-ART FACILITY DRAMATICALLY INCREASES CAPACITY FOR CLINICAL TRIALS AND OFFERS CLIENTS FIRST-OF-ITS-KIND CELL PROFILING CAPABILITIES COMBINING EPIGENETICS AND FLOW CYTOMETRY
London, UK, 28th November 2019 One Nucleus reveals the finalists of its annual BioNewsRound Award, recognising life science companies that have announced exciting developments for patient
Reading Scientific Services Ltd (RSSL) has expanded its microbiology capabilities with the launch of a fast, responsive and flexible sterility testing service for pharmaceutical and medical device companies.
Following the opening of its state-of-the-art microbiology laboratory earlier this year, RSSL has launched a sterility testing service in response to sustained client demand and market growth. The move enables the leading contract research organisation (CRO) to further enhance the scope of its biopharmaceutical services and increase testing capacity.